Search Within

Chung-Han Lee

Formats
  1. Meeting Abstract (79)
  2. Journal Article (63)
  3. Review (9)
  4. Research Letter (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (157)
  2. Genitourinary Oncology Service (157)
  3. Solid Tumor Oncology Division (157)
  4. Weinberg Fellows (85)
  5. Department of Pathology and Laboratory Medicine (59)
  6. Population Sciences Research Program (59)

More Groups

People
  1. Robert Motzer (109)
  2. Martin Voss (75)
  3. Darren Feldman (55)
  4. Maria Carlo (55)
  5. Abraham Hakimi (42)
  6. Ritesh Kotecha (42)

More People

Years
  1. 2025 (4)
  2. 2024 (9)
  3. 2023 (19)
  4. 2022 (23)
  5. 2021 (20)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (63)
  2. Annals of Oncology (9)
  3. Clinical Cancer Research (6)
  4. Clinical Genitourinary Cancer (6)
  5. European Urology (5)
  6. European Urology Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. Oxford University Press (13)
  3. Elsevier Inc. (11)
  4. Nature Publishing Group (11)
  5. American Association for Cancer Research (9)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (157)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Meeting Abstract

    Lee, C. H.; Li, C.; Perini, R. F.; Hoehn, D.; Albiges, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
    Journal Article

    Attalla, K.; DiNatale, R. G.; Rappold, P. M.; Fong, C. J.; Sanchez-Vega, F.; Silagy, A. W.; Weng, S.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • New approaches to first-line treatment of advanced renal cell carcinoma
    Review

    George, D. J.; Lee, C. H.; Heng, D.
    Therapeutic Advances in Medical Oncology (2021)

    Fulltext@MSK | Save
  • High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab
    Journal Article

    Lee, C. H.; DiNatale, R. G.; Chowell, D.; Krishna, C.; Makarov, V.; Valero, C.; Vuong, L.; Lee, M.; Weiss, K.; Hoen, D.; more...
    Molecular Cancer Research (2021)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1/PD-L1 checkpoint inhibitors
    Journal Article

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Li, H. A.; Regazzi, A. M.; Lee, C. H.; Funt, S. A.; Bajorin, D.; Ostrovnaya, I.; Iyer, G.; more...
    Journal of Immunotherapy (2021)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): A phase 1b/2 study
    Journal Article

    Lee, C. H.; Shah, A. Y.; Rasco, D.; Rao, A.; Taylor, M. H.; Di Simone, C.; Hsieh, J. J.; Pinto, A.; Shaffer, D. R.; Girones Sarrio, R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma
    Journal Article

    Lee, C. H.; Wan, Y.; Smith, A.; Xie, R.; Motzer, R. J.
    European Urology Open Science (2021)

    Fulltext@MSK | Save